A shifting landscape: Practice patterns and outcomes of cystic fibrosis and non-cystic fibrosis pediatric lung transplantation.

Abstract

New drugs may further decrease the need for lung transplant (LTx) in pediatric patients with cystic fibrosis (CF), but few studies highlight pediatric non-CF LTx characteristics and outcomes. The ISHLT registry was used to report morbidity, graft failure, and survival for primary pediatric (<18years) LTx performed 1990-2017. Recipient/donor characteristics and long-term outcomes were analyzed for CF and non-CF recipients. Survival was assessed using Kaplan-Meier curves. Of 2232 primary LTx, (43% in males), 918 (41%) were performed for non-CF indications; most commonly pulmonary hypertension (43%). Non-CF patients were younger (median age 11 vs. 15, p<.001), and more frequently on inotropes and/or extracorporeal membrane oxygenation (15% vs. 2.4%, p<.001) at transplant, compared to CF recipients. In-hospital major complications more commonly affected CF LTx recipients (57% vs. 48%, p=.003), but 30-day mortality was higher in the non-CF group (9% non-CF vs. 5% CF, p<.001). One-, five-, and ten-year mortality was 18%, 50%, and 65% for CF recipients, respectively, and 21%, 45%, and 58% for non-CF recipients (p=.01 at 10years). Five-year survival was significantly better for non-CF females versus CF females (56% vs. 48%, p=.013), but was similar between groups for males (55% vs. 54%, p=.305). While age was a late outcomes risk factor, pulmonary hypertension and later transplants eras were protective. Early mortality is higher and late mortality is lower in non-CF LTx. Current non-CF LTx outcomes leave room for improvement. Further study is needed to evaluate the effects of center volume and pediatric-specific experience on outcomes.